The 2018 annual meeting of the European Society for Medical Oncology (ESMO) turned out to be a grand cru for head and neck cancer, with two abstracts in this disease entity presented during the presidential sessions of the meeting. These two presentations, one on the use of immune checkpoint inhibition in the frontline treatment of recurrent/metastatic (R/M) Squamous Cell Carcinoma of the Head and Neck (HNSCC) and one evaluating treatment de-escalation in low-risk, p16-positive oropharyngeal cancer, form the lion’s share of this report. In addition to this data were presented of clinical trials looking at the potential of durvalumab plus danvatirsen, M7824, tipifarnib and SD-101 in the treatment of R/M SCCHN.